IV vs Oral Ketamine: Routes of Administration Compared

Overview

Ketamine can be administered through multiple routes, each with distinct pharmacokinetic profiles, clinical evidence bases, and practical considerations. Intravenous (IV) infusion and oral (swallowed) administration represent two ends of the spectrum in terms of bioavailability, clinical control, and patient convenience. Understanding the trade-offs between these routes is essential for both clinicians designing treatment protocols and patients navigating their options.

IV ketamine, typically delivered at 0.5 mg/kg over 40 minutes, has been the most extensively studied route for depression treatment and remains the clinical reference standard. Oral ketamine, prescribed as capsules, tablets, or compounded solutions, offers the potential for at-home treatment but with substantially different pharmacokinetics due to extensive first-pass hepatic metabolism.

Pharmacokinetics and Bioavailability

The most fundamental difference between IV and oral ketamine is bioavailability. IV administration delivers 100% of the dose directly into systemic circulation, producing predictable, high peak plasma concentrations. Oral ketamine undergoes extensive first-pass metabolism in the liver, primarily by CYP3A4 and CYP2B6 enzymes, resulting in bioavailability of only 17-24% (Peltoniemi et al., 2016). This means that roughly 75-83% of an oral dose is metabolized before reaching systemic circulation.

This first-pass metabolism has an important pharmacological consequence: it produces substantially higher levels of norketamine, ketamine's primary metabolite. Norketamine has approximately one-third the NMDA receptor affinity of ketamine but may contribute its own antidepressant effects through mechanisms that remain under investigation. The higher norketamine-to-ketamine ratio produced by oral dosing effectively creates a different pharmacological profile than IV administration.

Clinical: The high inter-individual variability in oral ketamine bioavailability (ranging from as low as 10% to as high as 35% in some studies) means that two patients receiving identical oral doses may achieve substantially different plasma concentrations. This variability is influenced by CYP enzyme polymorphisms, hepatic function, food intake, and concomitant medications. Dose titration guided by clinical response is essential with oral formulations.

Efficacy Evidence

IV Ketamine

IV ketamine at 0.5 mg/kg infused over 40 minutes is the most extensively studied ketamine regimen for depression. The evidence base includes:

• Over 40 randomized controlled trials demonstrating antidepressant efficacy
• Multiple meta-analyses confirming large effect sizes (Cohen's d approximately 0.8-1.0 at 24 hours)
• Response rates of 60-70% and remission rates of 30-40% within 24 hours
• Demonstrated efficacy for treatment-resistant depression, bipolar depression, PTSD, and suicidal ideation
• Established dose-response relationships

The landmark study by Berman et al. (2000) in Biological Psychiatry first demonstrated ketamine's rapid antidepressant effects. Zarate et al. (2006) confirmed these findings in a rigorous crossover design published in Archives of General Psychiatry, showing that a single 0.5 mg/kg IV infusion produced significant improvement within 110 minutes, with effects lasting up to 7 days.

Oral Ketamine

The evidence base for oral ketamine in depression is less robust than for IV administration but growing. Key findings include:

• Jafarinia et al. (2016) in Journal of Affective Disorders: oral ketamine (150 mg three times weekly) produced significant antidepressant effects compared with placebo over 6 weeks in treatment-resistant depression
• Arabzadeh et al. (2018): oral ketamine augmentation of sertraline showed significant improvement over sertraline plus placebo
• Multiple open-label and case series documenting efficacy for maintenance treatment following IV ketamine induction
• Smith-Apeldoorn et al. (2022) in British Journal of Psychiatry: a dose-finding RCT of oral esketamine for TRD demonstrated significant antidepressant effects at higher doses

However, the overall evidence quality is lower than for IV ketamine, with fewer large RCTs, more heterogeneous dosing protocols, and less standardized outcome assessment.

Treatment Settings and Monitoring

IV ketamine administration requires a clinical facility equipped for intravenous access, continuous vital sign monitoring, and emergency management of rare adverse events. This setting provides maximum safety but also maximum inconvenience -- patients must travel to a clinic, undergo IV placement, remain monitored for 1.5-2 hours total, and arrange transportation home.

Oral ketamine opens the possibility of at-home treatment with telemedicine monitoring. Many prescribers now utilize a model in which initial treatments are administered in-clinic to establish tolerability, followed by at-home dosing with remote monitoring via video call. This approach dramatically reduces the logistical burden on patients and enables treatment access for those in areas without nearby IV ketamine clinics.

Clinical: At-home oral ketamine protocols require robust patient selection and safety frameworks. Appropriate candidates should demonstrate tolerability during supervised initial sessions, have a responsible adult present during treatments, have no history of substance use disorder or ketamine misuse, and be engaged in concurrent psychiatric care. Clear protocols for emergency situations must be established before initiating home-based treatment.

Cost Comparison

The cost differential between IV and oral ketamine is substantial, driven primarily by the elimination of clinic overhead, nursing support, and IV-related supply costs. Compounded oral ketamine formulations are inexpensive, and telemedicine monitoring visits cost a fraction of in-person infusion sessions. For patients paying out-of-pocket -- as most ketamine therapy patients do -- this difference can be the determining factor in treatment accessibility and sustainability.

However, cost comparisons must account for efficacy differences. If oral ketamine requires higher doses or more frequent treatments, the cost advantage may narrow.

Dosing Considerations

The standard IV dose is 0.5 mg/kg over 40 minutes, well-established and predictable. Oral dosing is more complex: because only 17-24% reaches systemic circulation, oral doses of 1.0-3.0 mg/kg are typically required to approach comparable plasma levels. Common starting oral doses are 0.5-1.0 mg/kg, titrated based on response. Bioavailability optimization strategies include administration on an empty stomach, sublingual holding before swallowing, and attention to drug interactions affecting CYP3A4 activity.

Clinical Integration

Many clinicians utilize a stepped-care model that leverages the strengths of both routes:

1. Induction: IV ketamine for acute stabilization, leveraging superior bioavailability and evidence base
2. Transition: Gradual shift to oral maintenance once acute response is established
3. Maintenance: Oral ketamine at home with periodic telemedicine monitoring
4. Rescue: Return to IV ketamine for acute exacerbations or loss of oral treatment response

This approach optimizes the trade-off between clinical efficacy and practical sustainability, recognizing that the "best" route depends on the phase of treatment and individual patient circumstances.

References

• Berman RM, Cappiello A, Anand A, et al. (2000). Antidepressant effects of ketamine in depressed patients. Biological Psychiatry, 47(4), 351-354. PubMed
• Jafarinia M, Afarideh M, Tafakhori A, et al. (2016). Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial. Journal of Affective Disorders, 204, 1-8. PubMed
• Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI (2016). Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy. Clinical Pharmacokinetics, 55(9), 1059-1077. PubMed
• Smith-Apeldoorn SY, Veraart JKE, Kamphuis J, et al. (2022). Oral esketamine for treatment-resistant depression: a pragmatic randomized controlled trial. British Journal of Psychiatry, 220(3), 141-148. PubMed
• Zarate CA Jr, Singh JB, Carlson PJ, et al. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant depression. Archives of General Psychiatry, 63(8), 856-864. PubMed
• National Institute of Mental Health (NIMH). Mental Health Medications. NIMH